Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors.

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors.

Blood - 1 Dec 1995

O'Connor R, Liu C, Ferris C A, Guild B C, Teicher B A, Corvi C, Liu Y, Arceci R J, Goldmacher V S, Lambert J M, Blättler W A

Abstract excerpt

Anti-B4-blocked ricin (anti-B4-bR) is an immunotoxin directed against CD19-positive cells that is currently being tested in several B-cell leukemia/lymphoma clinical trials. To explore the possibility of using anti-B4-bR in combination with chemotherapy protocols, we investigated the in vitro and...

Topics

ATP Binding Cassette Transporter, Subfamily B, Member 1
Animals
Antigens, CD19
Burkitt Lymphoma
Doxorubicin
Drug Resistance, Multiple
Drug Synergism
Etoposide
Genotype
Humans
Immunotoxins
Mice
Mice, SCID
Ricin
Tumor Cells, Cultured

Source

Open in PubMed

Identifiers

PMID: 7492789

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-7492789-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics